Method for separating and / or detecting ozagrel synthetic intermediate and related substances thereof
Through high-performance liquid chromatography, the separation and detection problems of Ozagrel synthesis intermediate and related substances were solved by using octadecylsilane bonded silica gel chromatography column and gradient elution program, the problem of separation and detection of Ozagrel synthesis intermediate and related substances was achieved, the quality control of drugs was achieved, and the drug was improved. Safety and effectiveness of clinical applications.
Patent Information
- Application Number
- CN202410686697.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-30
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing isolation and detection methods of the compounds of formula II and their related substances of Ozagrel have not been reported, making it difficult to effectively control the purity and quality of the drug, affecting the clinical application of the drug.
Using high-performance liquid chromatography, using octadecylsilane-bonded silica gel chromatography column, the mobile phase consists of aqueous phosphoric acid solution and acetonitrile, and the effective separation and detection of Ozagrel synthesis intermediates and related substances are achieved through gradient elution procedures. , Welch Ultimate XS C18 chromatography column was selected, the column temperature was 20℃-30℃, and the mobile phase gradient elution program and ultraviolet detector were detected at 208-212nm.
The effective separation and detection of Ozagrel synthesis intermediates and related substances is achieved, ensuring the quality control of drugs, reducing the possibility of adverse drug reactions, and improving the effectiveness and safety of drugs.
Smart Images

Figure CN118980752A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of drug analysis, and in particular to a method for separating and / or detecting an ozagrel synthetic intermediate and related substances thereof. Background Art
[0002] Sodium ozagrel is a highly potent and selective thromboxane synthetase inhibitor. 2 (TXA 2 ) and promote the production of prostacyclin (PGI 2 ) to improve the imbalance between the two, and has the effects of anti-platelet aggregation and vasodilation. It was first launched by Ono Pharmaceutical Co., Ltd. in 1989 and is mainly used in the treatment of acute thrombotic cerebral infarction and movement disorders associated with cerebral infarction. Ozagrel's chemical name is (E)-3-(imidazolyl-1-methyl)cinnamic acid, and its structure is as follows: Formula I.
[0003]
[0004] The compound of formula II is a key intermediate for preparing ozagrel (Route 1 is a preparation process of ozagrel sodium).
[0005]
[0006] Drug impurities are divided into process impurities (including reactants and reagents, intermediates, by-products, etc. that have not reacted completely during preparation), degradation products, impurities mixed from reactants and reagents, etc. The control and analysis of impurities in the intermediates of each step in the preparation of the API directly determines the purity and quality of the final API. In actual work, R&D personnel need to analyze and control the impurities of the starting materials in the synthesis of the API and the intermediates of each step of the reaction. There is no report on the relevant impurities and separation and detection methods of the key intermediate in the preparation of Ozagrel, namely the above-mentioned compound of formula II. It is of great industrial value to develop a method that can efficiently separate and detect the compound of formula II and its related substances. Summary of the invention
[0007] The purpose of the present invention is, on the one hand, to provide a method for separating and / or detecting an ozagrel synthetic intermediate compound shown in formula II and its related substances, which includes the following features: high performance liquid chromatography is used, the stationary phase of the chromatographic column is octadecylsilane bonded silica gel, the mobile phase is composed of phase A and phase B, phase A is phosphoric acid aqueous solution, phase B is acetonitrile, the mobile phase is gradient elution, and the related substances are selected from any one of related substance 1, related substance 2, related substance 3, related substance 4, related substance 5, related substance 6, and related substance 7 or a combination thereof:
[0008]
[0009] In the preferred technical scheme of the present invention, the octadecylsilane bonded silica gel chromatographic column is selected from Eclipse Plus C18, Kromasil 100-5-C18, Kromasil Eternity-5-C18, Kromasil Eternity XT-10-C18, Kromasil 100-10-C18, Kromasil 300-5-C18, YMC Triat C18, YMC ODS C18, YMC-Pack Pro C18, Phenomenex kinetex C18, phenomenex Luna PFP (2) 100A, Agilent ZORBAX SB-C18, Poroshell 120EC-C18, Bonshell C18, Bonshell ASB C18, Venusil HLP C18, Venusil C18Plus, Venusil XBP C18 (A), Venusil XBP C18 (B), Venusil MP C18, Innoval Neo XD C18, Techmate C18-ST, Techmate C18-STⅡ, Techmate CI8 UG, Agilent Microspher C18, Agilent InfinityLab Poroshell 120EC-C18, Waters Xselect CSH Fluoro-Phenyl, DAICEL Chiralcel OD-RH, Welch Ultimate XS C18 or any combination thereof.
[0010] In a preferred technical solution of the present invention, the octadecylsilane bonded silica gel chromatographic column is preferably Welch Ultimate XS C18.
[0011] In a preferred technical solution of the present invention, the chromatographic column is specifically Welch Ultimate XS C18, 4.6mm×250mm, 5μm.
[0012] In a preferred technical solution of the present invention, the column temperature of the chromatographic column is 18°C-32°C, preferably 20°C-30°C, and more preferably 23-27°C.
[0013] In a preferred technical solution of the present invention, the volume concentration of the phase A phosphoric acid aqueous solution is 0.01-1%, preferably 0.05-0.5%, and more preferably 0.05-0.25%.
[0014] In the preferred technical solution of the present invention, the gradient elution procedure is:
[0015]
[0016] The preferred gradient elution program is:
[0017]
[0018] In the preferred technical solution of the present invention, the flow rate of the mobile phase is 0.7ml / min-1.3ml / min, preferably 0.9ml / min-1.1ml / min.
[0019] In the preferred technical solution of the present invention, the method is equipped with an ultraviolet detector, and the detection wavelength of the ultraviolet detector is 200nm-220nm, preferably 205nm-215nm, and more preferably 208nm-212nm.
[0020] In a preferred technical solution of the present invention, the injection volume of the method is 1-10 μl, preferably 1-8 μl, and more preferably 1-5 μl.
[0021] In the preferred technical scheme of the present invention, the order of peaks is related substance 1, related substance 2, related substance 3, related substance 4, related substance 5, related substance 6, related substance 7 and compound of formula II, wherein the separation between the peaks of the related substances and between the peak of the compound of formula II and the peak of the adjacent compound are both greater than 1.5.
[0022] In the preferred technical solution of the present invention, the method comprises the following steps:
[0023] 1) Solution preparation:
[0024] Solvent: acetonitrile-water with a volume ratio of 1:1;
[0025] Test solution: Take an appropriate amount of the compound of formula II and prepare a solution with a concentration of about 1 mg / ml using a solvent;
[0026] System suitability solution: Weigh appropriate amounts of related substances 1-7 and reference substance of compound of formula II respectively, dissolve and dilute with solvent to prepare a mixed solution containing about 3 μg of each related substance and about 1 mg of compound of formula II per 1 ml;
[0027] 2) A chromatographic column Welch Ultimate XS-C18, 4.6 mm × 250 mm, 5 μm was used as the stationary phase, the column temperature was 20° C.-30° C., the mobile phase consisted of phase A and phase B, phase A was 0.1% (V / V) phosphoric acid aqueous solution, phase B was acetonitrile, and the mobile phase was gradient elution. The gradient elution procedure was as follows:
[0028] ,
[0029] Inject the eluted sample into the liquid chromatograph with an injection volume of 5 μl, a detection wavelength of the UV detector of 208-212 nm, a flow rate of 0.9 ml / min-1.1 ml / min, and elute and record the chromatogram.
[0030] In the preferred technical solution of the present invention, the method comprises the following steps:
[0031] 1) Solution preparation:
[0032] Solvent: acetonitrile-water with a volume ratio of 1:1;
[0033] Test solution: Take an appropriate amount of the compound of formula II and prepare a solution with a concentration of about 1 mg / ml using a solvent;
[0034] System suitability solution: Weigh appropriate amounts of related substances 1-7 and reference substance of compound of formula II respectively, dissolve and dilute with solvent to prepare a mixed solution containing about 3 μg of each related substance and about 1 mg of compound of formula II per 1 ml;
[0035] 2) A chromatographic column Welch Ultimate XS-C18, 4.6 mm × 250 mm, 5 μm was used as the stationary phase, the column temperature was 25° C., the mobile phase consisted of phase A and phase B, phase A was 0.1% (V / V) phosphoric acid aqueous solution, phase B was acetonitrile, and the mobile phase was gradient elution. The gradient elution procedure was as follows:
[0036] ,
[0037] Inject the eluted sample into the liquid chromatograph with an injection volume of 5 μl, a detection wavelength of the UV detector of 210 nm, a flow rate of 1 ml / min, and elute and record the chromatogram.
[0038] Another object of the present invention is to provide an application of the method described in the present invention in separating and / or detecting the ozagrel synthetic intermediate compound shown in formula II and its related substances.
[0039] Unless otherwise specified, when the present invention relates to the percentage between liquids, the percentage is volume / volume percentage; when the present invention relates to the percentage between liquids and solids, the percentage is volume / weight percentage; when the present invention relates to the percentage between solids and liquids, the percentage is weight / volume percentage; the rest are weight / weight percentages.
[0040] Compared with the prior art, the present invention has the following beneficial effects:
[0041] The present invention realizes effective separation and detection of ozagrel synthetic intermediate compound II and its related substances, which are 8 compounds with similar structures and difficult to separate, by scientifically screening and optimizing the elution conditions and detection conditions of high performance liquid chromatography. Among them, related substance 3 is a genotoxic impurity, and the remaining compounds are general process impurities. The separation effect is good, the quality control of ozagrel synthetic intermediate compound II and the final product ozagrel is guaranteed, the quality of prepared drugs is significantly improved, the adverse reactions that may occur in drug clinical trials and treatments are reduced, and the effectiveness and safety of patients' medication are guaranteed. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 It is the high performance liquid chromatogram of Comparative Example 1.
[0043] Figure 2 It is the high performance liquid chromatogram of Comparative Example 2.
[0044] Figure 3 It is the high performance liquid chromatogram of comparative example 3.
[0045] Figure 4 It is the high performance liquid chromatogram of Comparative Example 4.
[0046] Figure 5 It is the high performance liquid chromatogram of Example 1.
[0047] Figure 6 It is the high performance liquid chromatogram of Example 2. DETAILED DESCRIPTION
[0048] To make the purpose, technical solution and advantages of the present invention more clear, the embodiments of the present invention will be described in detail with reference to the accompanying drawings. It should be noted that the embodiments of the present invention and the features in the embodiments can be combined with each other arbitrarily without conflict.
[0049] Comparative Example 1 HPLC separation and detection of compound II and related substances
[0050] Liquid chromatograph: Agilent 1260;
[0051] Column: Agilent InfinityLab Poroshell 120EC-C18, 150 mm × 4.6 mm, 2.7 μm;
[0052] Column temperature: 30°C;
[0053] Mobile phase: Phase A is 0.1% phosphoric acid aqueous solution, phase B is acetonitrile;
[0054] Gradient elution program:
[0055]
[0056] Flow rate: 1.0ml / min;
[0057] UV detector detection wavelength: 210nm;
[0058] Solvent: acetonitrile-water (1:1);
[0059] Injection volume: 5 μl;
[0060] Mixed solution: Take appropriate amounts of related substances 3-7 and the compound of formula II and prepare a mixed solution with a solvent (the concentration of related substance 3 is about 20 μg / ml, the concentration of related substances 4-7 is about 2 μg / ml, and the concentration of the compound of formula II is about 0.1 mg / ml).
[0061] Chromatographic results are shown in Figure 1 The results showed that some chromatographic peaks overlapped and could not be effectively separated and detected, and could not be used to control product quality.
[0062] Comparative Example 2 HPLC separation and detection of the compound of formula II and related substances
[0063] Liquid chromatograph: Agilent 1260;
[0064] Chromatographic column: Waters, Xselect CSH Fluoro-Phenyl, 150 mm × 4.6 mm, 3.5 μm;
[0065] Column temperature: 30°C;
[0066] Mobile phase: Phase A is 0.1% phosphoric acid aqueous solution, phase B is acetonitrile;
[0067] Gradient elution program:
[0068]
[0069]
[0070] Flow rate: 1.0ml / min;
[0071] UV detector detection wavelength: 210nm;
[0072] Solvent: acetonitrile-water (1:1);
[0073] Injection volume: 5 μl;
[0074] Mixed solution: Take appropriate amounts of related substances 3-7 and the compound of formula II and prepare a mixed solution with a solvent (the concentration of related substance 3 is about 20 μg / ml, the concentration of related substances 4-7 is about 2 μg / ml, and the concentration of the compound of formula II is about 0.1 mg / ml).
[0075] Chromatographic results are shown in Figure 2 The results showed that there were still overlapping chromatographic peaks, which could not be effectively separated and detected and could not be used to control product quality.
[0076] Comparative Example 3 HPLC separation and detection of the compound of formula II and related substances
[0077] Liquid chromatograph: Agilent 1260;
[0078] Chromatographic column: Agilent, ZORBAX SB-C18, 150 mm × 4.6 mm, 1.8 μm;
[0079] Column temperature: 30°C;
[0080] Mobile phase: Phase A is 0.1% phosphoric acid aqueous solution, phase B is acetonitrile;
[0081] Gradient elution program:
[0082]
[0083] Flow rate: 1.0ml / min;
[0084] UV detector detection wavelength: 210nm;
[0085] Solvent: acetonitrile-water (1:1);
[0086] Injection volume: 5 μl;
[0087] Mixed solution: Take appropriate amounts of related substances 2-7 and the compound of formula II and prepare a mixed solution with a solvent (the concentration of each related substance is about 2 μg / ml, and the concentration of the compound of formula II is about 1 mg / ml).
[0088] Chromatographic results are shown in Figure 3 The results showed that there were overlapping chromatographic peaks, which could not be effectively separated and detected and could not be used to control product quality.
[0089] Comparative Example 4 HPLC separation and detection of compound II and related substances
[0090] Liquid chromatograph: Agilent 1260;
[0091] Chromatographic column: Agilent, ZORBAX SB-C18, 150 mm × 4.6 mm, 1.8 μm;
[0092] Column temperature: 30°C;
[0093] Mobile phase: Phase A is 0.05% trifluoroacetic acid aqueous solution, phase B is acetonitrile;
[0094] Gradient elution program:
[0095]
[0096] Flow rate: 1.0ml / min;
[0097] UV detector detection wavelength: 210nm;
[0098] Solvent: acetonitrile-water (1:1);
[0099] Injection volume: 5 μl;
[0100] Mixed solution: Take appropriate amounts of related substances 2-7 and the compound of formula II and prepare a mixed solution with a solvent (the concentration of each related substance is about 2 μg / ml, and the concentration of the compound of formula II is about 1 mg / ml).
[0101] Chromatographic results are shown in Figure 4 The results showed that the peak elution was improved, but it still could not be effectively separated and detected. In addition, using trifluoroacetic acid as the mobile phase was highly dangerous.
[0102] Example 1 HPLC separation and detection of compound of formula II and related substances
[0103] Liquid chromatograph: Agilent 1260;
[0104] Column: Welch Ultimate XS C18, 4.6 mm × 250 mm, 5 μm;
[0105] Column temperature: 25°C;
[0106] Mobile phase: Phase A is 0.1% (V / V) phosphoric acid aqueous solution, and phase B is acetonitrile;
[0107] Gradient elution program:
[0108]
[0109]
[0110] Flow rate: 1.0ml / min;
[0111] UV detector detection wavelength: 210nm;
[0112] Solvent: 50% acetonitrile solution;
[0113] Injection volume: 5 μl;
[0114] Mixed solution: Take appropriate amounts of related substances 1-7 and the compound of formula II and prepare a mixed solution with a solvent (the concentration of each related substance is about 2 μg / ml, and the concentration of the compound of formula II is about 1 mg / ml).
[0115] Chromatographic results are shown in Figure 5 The results showed that all compounds were present and the separation between adjacent components was good.
[0116] Example 2 Specificity of the HPLC method of the present invention
[0117] Liquid chromatograph: Agilent 1260;
[0118] Column: Welch Ultimate XS C18, 4.6 mm × 250 mm, 5 μm;
[0119] Column temperature: 25°C;
[0120] Mobile phase: Phase A is 0.1% (V / V) phosphoric acid aqueous solution, and phase B is acetonitrile;
[0121] Gradient elution program:
[0122]
[0123] Flow rate: 1.0ml / min;
[0124] UV detector detection wavelength: 210nm;
[0125] Solvent: 50% acetonitrile solution;
[0126] Injection volume: 5 μl;
[0127] Positioning solution: Weigh appropriate amounts of related substances 1-7 and reference compound of formula II respectively, dissolve and dilute with 50% acetonitrile solution to prepare solutions containing about 100 μg of each related substance and about 1 mg of compound of formula II per 1 ml, as the positioning solutions.
[0128] System suitability solution: Weigh appropriate amounts of related substances 1-7 and reference compound of formula II respectively, dissolve and dilute with 50% acetonitrile solution to prepare a mixed solution containing about 3 μg of each related substance and about 1 mg of compound of formula II per 1 ml.
[0129] The system suitability solution chromatography results are shown in Table 1 and Figure 6 .
[0130] Table 1
[0131]
[0132] The results showed that under this method, the minimum separation between each impurity peak and between each impurity peak and the main component peak was 3.03, which was greater than 1.5, and the specificity was good.
[0133] Example 3 Sensitivity of the HPLC method of the present invention
[0134] The chromatographic conditions were the same as in Example 1.
[0135] Solution preparation: Take appropriate amounts of related substances 1-7 and reference compound of formula II respectively, weigh accurately, dissolve in 50% acetonitrile solution and quantitatively dilute to prepare solutions of appropriate concentrations. The signal-to-noise ratio S / N of the peak height of each component ≥10 is the quantitative limit solution; the signal-to-noise ratio S / N of each component ≥3 is the detection limit solution. The sensitivity results are shown in Table 2 below.
[0136] Table 2
[0137]
[0138]
[0139] The results show that the method of the present invention is highly sensitive in detecting the compound of formula II and related substances, and quantitative detection can be completed at a level as low as ng for each compound.
[0140] Example 4 Durability of the HPLC Method of the Present Invention
[0141] System suitability solution: Weigh appropriate amounts of related substances 1-7 and reference compound of formula II respectively, dissolve and dilute with 50% acetonitrile solution to prepare a mixed solution containing about 3 μg of each related substance and about 1 mg of compound of formula II per 1 ml.
[0142] The retention time, separation degree, tailing factor and theoretical plate number of each compound are shown in Table 3 below.
[0143] Table 3
[0144]
[0145]
[0146]
[0147] The results show that after slight adjustments to the chromatographic conditions of Example 1 of the present invention, including flow rate, column temperature, wavelength, gradient elution program, and instrument, the separation degree, tailing factor, and theoretical plate number of each related substance still meet the requirements, and the durability of the method of the present invention is good.
[0148] Although the embodiments disclosed in the present invention are as above, the contents described are only embodiments adopted to facilitate understanding of the present invention and are not intended to limit the present invention. Any technician in the field to which the present invention belongs can make any modifications and changes in the form and details of the implementation without departing from the spirit and scope disclosed in the present invention, but the patent protection scope of the present invention shall still be subject to the scope defined in the attached claims.
Claims
1. A method for separating and / or detecting an ozagrel synthetic intermediate compound shown in formula II and its related substances, comprising the following features: using high performance liquid chromatography, the chromatographic column stationary phase is octadecylsilane bonded silica gel, the mobile phase is composed of phase A and phase B, the phase A is phosphoric acid aqueous solution, the phase B is acetonitrile, the mobile phase is gradient elution, and the related substance is selected from any one of related substance 1, related substance 2, related substance 3, related substance 4, related substance 5, related substance 6, and related substance 7 or a combination thereof: 。 2. The method according to claim 1, characterized in that: The chromatographic column is Welch Ultimate XS C18, preferably Welch Ultimate XS C18, 4.6 mm×250 mm, 5 μm.
3. The method according to any one of claims 1 to 2, characterized in that: The column temperature of the chromatographic column is 18-32°C, preferably 20-30°C, more preferably 23-27°C, and the volume concentration of the phase A phosphoric acid aqueous solution is 0.01-1%, preferably 0.05-0.5%, more preferably 0.05-0.25%.
4. The method according to any one of claims 1 to 3, characterized in that: The gradient elution procedure is: , Preferably, the gradient elution procedure is:
5. The method according to any one of claims 1 to 4, characterized in that: The flow rate of the mobile phase is 0.7ml / min-1.3ml / min, preferably 0.9ml / min-1.1ml / min. The method is equipped with an ultraviolet detector, and the detection wavelength of the ultraviolet detector is 200nm-220nm, preferably 205nm-215nm, and more preferably 208nm-212nm. The injection volume of the method is 1-10μl, preferably 1-8μl, and more preferably 1-5μl.
6. The method according to any one of claims 1 to 5, characterized in that: The peak elution order of the high performance liquid chromatography is related substance 1, related substance 2, related substance 3, related substance 4, related substance 5, related substance 6, related substance 7 and compound of formula II, wherein the separation between the peaks of the related substances and between the peak of the compound of formula II and the peak of the adjacent compound are both greater than 1.
5.
7. The method according to any one of claims 1 to 6, characterized in that: The method comprises the following steps: 1) Solution preparation: Solvent: acetonitrile-water with a volume ratio of 1:1 Test solution: Take an appropriate amount of the compound of formula II and prepare a solution with a concentration of about 1 mg / ml using a solvent; System suitability solution: Weigh appropriate amounts of related substances 1-7 and reference substance of compound of formula II respectively, dissolve and dilute with solvent to prepare a mixed solution containing about 3 μg of each related substance and about 1 mg of compound of formula II per 1 ml; 2) The stationary phase was Welch Ultimate XS-C18, 4.6 mm × 250 mm, 5 μm. The column temperature is 20°C-30°C, the mobile phase consists of phase A and phase B, phase A is 0.1% (V / V) phosphoric acid aqueous solution, phase B is acetonitrile, and the mobile phase is gradient elution. The gradient elution procedure is as follows: , Inject the eluted sample into the liquid chromatograph with an injection volume of 5 μl, a detection wavelength of the UV detector of 208-212 nm, a flow rate of 0.9 ml / min-1.1 ml / min, and elute and record the chromatogram.
8. The method according to claim 7, characterized in that The method comprises the following steps: 1) Solution preparation: Solvent: acetonitrile-water with a volume ratio of 1:1; Test solution: Take an appropriate amount of the compound of formula II and prepare a solution with a concentration of about 1 mg / ml using a solvent; System suitability solution: Weigh appropriate amounts of related substances 1-7 and reference substance of compound of formula II respectively, dissolve and dilute with solvent to prepare a mixed solution containing about 3 μg of each related substance and about 1 mg of compound of formula II per 1 ml; 2) The stationary phase was Welch Ultimate XS-C18, 4.6 mm × 250 mm, 5 μm. The column temperature was 25°C, the mobile phase consisted of phase A and phase B, phase A was 0.1% (V / V) phosphoric acid aqueous solution, phase B was acetonitrile, and the mobile phase was gradient elution. The gradient elution procedure was as follows: , Inject the eluted sample into the liquid chromatograph with an injection volume of 5 μl, a detection wavelength of the UV detector of 210 nm, a flow rate of 1 ml / min, and elute and record the chromatogram.
9. Use of the method according to any one of claims 1 to 8 for separating and / or detecting the ozagrel synthetic intermediate compound represented by formula II and its related substances.
